Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma
- 1 September 1999
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 7 (9) , 1775-1780
- https://doi.org/10.1016/s0968-0896(99)00126-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- New Mustard Prodrugs for Antibody-Directed Enzyme Prodrug Therapy: Alternatives to the Amide LinkJournal of Medicinal Chemistry, 1996
- Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug TherapyJournal of Medicinal Chemistry, 1995
- Activity of Extracts ofKigelia pinnataAgainst Melanoma and Renal Carcinoma Cell LinesPlanta Medica, 1994
- Design of Antitumor Prodrugs: Substrates for Antibody Targeted EnzymesChemical Reviews, 1994
- Novel Prodrugs of Alkylating Agents Derived from 2-Fluoro- and 3-Fluorobenzoic Acids for Antibody-Directed Enzyme Prodrug TherapyJournal of Medicinal Chemistry, 1994
- Comparison of tyrosinase activity and stability in aqueous and nearly nonaqueous environmentsEnzyme and Microbial Technology, 1993
- Activity of mushroom polyphenol oxidase in organic mediumBiotechnology & Bioengineering, 1993
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- New regulators of melanin biosynthesis and the autodestruction of melanoma cellsNature, 1980
- 460. Cytotoxic compounds. Part II. Some amides of the “nitrogen mustard” typeJournal of the Chemical Society, 1961